| BRAF mutants evade ERK-dependent feedback by different mechanisms that determine their sensitivity to pharmacologic inhibition Z Yao, NM Torres, A Tao, Y Gao, L Luo, Q Li, E de Stanchina, ... Cancer cell 28 (3), 370-383, 2015 | 461 | 2015 |
| Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS Z Yao, R Yaeger, VS Rodrik-Outmezguine, A Tao, NM Torres, MT Chang, ... Nature 548 (7666), 234-238, 2017 | 459 | 2017 |
| Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor VS Rodrik-Outmezguine, M Okaniwa, Z Yao, CJ Novotny, C McWhirter, ... Nature 534 (7606), 272-276, 2016 | 452 | 2016 |
| Diverse and targetable kinase alterations drive histiocytic neoplasms EL Diamond, BH Durham, J Haroche, Z Yao, J Ma, SA Parikh, Z Wang, ... Cancer discovery 6 (2), 154-165, 2016 | 443 | 2016 |
| TGF-β IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer Z Yao, S Fenoglio, DC Gao, M Camiolo, B Stiles, T Lindsted, ... Proceedings of the National Academy of Sciences 107 (35), 15535-15540, 2010 | 433 | 2010 |
| Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence MH Nissan, CA Pratilas, AM Jones, R Ramirez, H Won, C Liu, S Tiwari, ... Cancer research 74 (8), 2340-2350, 2014 | 348 | 2014 |
| Rapid induction of apoptosis by PI3K inhibitors is dependent upon their transient inhibition of RAS–ERK signaling M Will, ACR Qin, W Toy, Z Yao, V Rodrik-Outmezguine, C Schneider, ... Cancer discovery 4 (3), 334-347, 2014 | 199 | 2014 |
| RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling Z Yao, Y Gao, W Su, R Yaeger, J Tao, N Na, Y Zhang, C Zhang, A Rymar, ... Nature medicine 25 (2), 284-291, 2019 | 156 | 2019 |
| Allele-specific mechanisms of activation of MEK1 mutants determine their properties Y Gao, MT Chang, D McKay, N Na, B Zhou, R Yaeger, NM Torres, ... Cancer discovery 8 (5), 648-661, 2018 | 116 | 2018 |
| A Braf kinase-inactive mutant induces lung adenocarcinoma P Nieto, C Ambrogio, L Esteban-Burgos, G Gómez-López, MT Blasco, ... Nature 548 (7666), 239-243, 2017 | 105 | 2017 |
| Extreme outlier analysis identifies occult mitogen-activated protein kinase pathway mutations in patients with low-grade serous ovarian cancer RN Grisham, BE Sylvester, H Won, G McDermott, D DeLair, R Ramirez, ... Journal of clinical oncology 33 (34), 4099, 2015 | 100 | 2015 |
| Response to anti-EGFR therapy in patients with BRAF non-V600–mutant metastatic colorectal cancer R Yaeger, D Kotani, S Mondaca, AR Parikh, H Bando, EE Van Seventer, ... Clinical Cancer Research 25 (23), 7089-7097, 2019 | 99 | 2019 |
| Mechanistically distinct cancer-associated mTOR activation clusters predict sensitivity to rapamycin J Xu, CG Pham, SK Albanese, Y Dong, T Oyama, CH Lee, ... The Journal of clinical investigation 126 (9), 3526-3540, 2016 | 94 | 2016 |
| p53Ψ is a transcriptionally inactive p53 isoform able to reprogram cells toward a metastatic-like state S Senturk, Z Yao, M Camiolo, B Stiles, T Rathod, AM Walsh, ... Proceedings of the National Academy of Sciences 111 (32), E3287-E3296, 2014 | 93 | 2014 |
| A brain-penetrant RAF dimer antagonist for the noncanonical BRAF oncoprotein of pediatric low-grade astrocytomas Y Sun, JA Alberta, C Pilarz, D Calligaris, EJ Chadwick, SH Ramkissoon, ... Neuro-oncology 19 (6), 774-785, 2017 | 91 | 2017 |
| Mutant-selective degradation by BRAF-targeting PROTACs S Alabi, S Jaime-Figueroa, Z Yao, Y Gao, J Hines, KTG Samarasinghe, ... Nature communications 12 (1), 920, 2021 | 90 | 2021 |
| Mechanisms of acquired resistance to BRAF V600E inhibition in colon cancers converge on RAF dimerization and are sensitive to its inhibition R Yaeger, Z Yao, DM Hyman, JF Hechtman, E Vakiani, HY Zhao, W Su, ... Cancer research 77 (23), 6513-6523, 2017 | 72 | 2017 |
| B23 acts as a nucleolar stress sensor and promotes cell survival through its dynamic interaction with hnRNPU and hnRNPA1 Z Yao, S Duan, D Hou, W Wang, G Wang, Y Liu, L Wen, M Wu Oncogene 29 (12), 1821-1834, 2010 | 66 | 2010 |
| A Secondary Mutation in BRAF Confers Resistance to RAF Inhibition in a BRAFV600E-Mutant Brain Tumor J Wang, Z Yao, P Jonsson, AN Allen, ACR Qin, S Uddin, IJ Dunkel, ... Cancer discovery 8 (9), 1130-1141, 2018 | 64 | 2018 |
| Phosphorylation of Pirh2 by Calmodulin‐dependent kinase II impairs its ability to ubiquitinate p53 S Duan, Z Yao, D Hou, Z Wu, W Zhu, M Wu The EMBO journal 26 (13), 3062-3074, 2007 | 61 | 2007 |
